{"title":"新型fap靶向配体68Ga-DOTA-FL在结肠癌小动物PET/CT成像中的初步研究","authors":"Zhan Xu, Yimeng Shi, Hongyan Yin, Jing Lv","doi":"10.1007/s40336-023-00603-2","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>This study explored the feasibility of <sup>68</sup>gallium (Ga)-labeled novel fibroblast activation protein (FAP)-targeted ligand for tumor imaging through small-animal PET/CT (positron emission computed tomography/computed tomography).</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>The FAP-ligand (FL) was created by adding the chelating group dodecane tetraacetic acid (DOTA) and labeling with <sup>68</sup>Ga. The MC38 cell line was used to establish a C57BL/6 mice colon cancer model. The radioactivity distribution of labeled <sup>68</sup>Ga-DOTA-FL across various organs of the mouse model was examined ex-vivo. In addition, <sup>68</sup>Ga-DOTA-FL tumor-targeted imaging in vivo was performed using small-animal PET/CT. Finally, western blotting and immunofluorescence imaging of MC38 cells and xenotransplant tumor tissues were conducted.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>The radiolabeling rate and radiochemical purity of <sup>68</sup>Ga-DOTA-FL were above 95%. Both western blotting and immunofluorescence imaging revealed FAP expression in the tumor tissues, but not in the MC38 cells. Small-animal PET/CT imaging indicated that the tumor imaging was clearest at 30 min after <sup>68</sup>Ga-DOTA-FL treatment. Examination of the radioactivity distribution in vitro revealed that at 30 min after the <sup>68</sup>Ga-DOTA-FL treatment, the target/non-target ratio for tumor and muscle tissue was 4.0 ± 0.3 (<i>n</i> = 3).</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p><sup>68</sup>Ga-DOTA-FL can be used for the specific tumor imaging in mouse models, which might provide a novel alternative for FAP-targeted tumor imaging.</p>","PeriodicalId":48600,"journal":{"name":"Clinical and Translational Imaging","volume":"63 1","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2023-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Preliminary study of a novel FAP-targeted ligand 68Ga-DOTA-FL in colon cancer imaging using small-animal PET/CT\",\"authors\":\"Zhan Xu, Yimeng Shi, Hongyan Yin, Jing Lv\",\"doi\":\"10.1007/s40336-023-00603-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<h3 data-test=\\\"abstract-sub-heading\\\">Purpose</h3><p>This study explored the feasibility of <sup>68</sup>gallium (Ga)-labeled novel fibroblast activation protein (FAP)-targeted ligand for tumor imaging through small-animal PET/CT (positron emission computed tomography/computed tomography).</p><h3 data-test=\\\"abstract-sub-heading\\\">Methods</h3><p>The FAP-ligand (FL) was created by adding the chelating group dodecane tetraacetic acid (DOTA) and labeling with <sup>68</sup>Ga. The MC38 cell line was used to establish a C57BL/6 mice colon cancer model. The radioactivity distribution of labeled <sup>68</sup>Ga-DOTA-FL across various organs of the mouse model was examined ex-vivo. In addition, <sup>68</sup>Ga-DOTA-FL tumor-targeted imaging in vivo was performed using small-animal PET/CT. Finally, western blotting and immunofluorescence imaging of MC38 cells and xenotransplant tumor tissues were conducted.</p><h3 data-test=\\\"abstract-sub-heading\\\">Results</h3><p>The radiolabeling rate and radiochemical purity of <sup>68</sup>Ga-DOTA-FL were above 95%. Both western blotting and immunofluorescence imaging revealed FAP expression in the tumor tissues, but not in the MC38 cells. Small-animal PET/CT imaging indicated that the tumor imaging was clearest at 30 min after <sup>68</sup>Ga-DOTA-FL treatment. Examination of the radioactivity distribution in vitro revealed that at 30 min after the <sup>68</sup>Ga-DOTA-FL treatment, the target/non-target ratio for tumor and muscle tissue was 4.0 ± 0.3 (<i>n</i> = 3).</p><h3 data-test=\\\"abstract-sub-heading\\\">Conclusions</h3><p><sup>68</sup>Ga-DOTA-FL can be used for the specific tumor imaging in mouse models, which might provide a novel alternative for FAP-targeted tumor imaging.</p>\",\"PeriodicalId\":48600,\"journal\":{\"name\":\"Clinical and Translational Imaging\",\"volume\":\"63 1\",\"pages\":\"\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2023-11-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Translational Imaging\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s40336-023-00603-2\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Imaging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40336-023-00603-2","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
Preliminary study of a novel FAP-targeted ligand 68Ga-DOTA-FL in colon cancer imaging using small-animal PET/CT
Purpose
This study explored the feasibility of 68gallium (Ga)-labeled novel fibroblast activation protein (FAP)-targeted ligand for tumor imaging through small-animal PET/CT (positron emission computed tomography/computed tomography).
Methods
The FAP-ligand (FL) was created by adding the chelating group dodecane tetraacetic acid (DOTA) and labeling with 68Ga. The MC38 cell line was used to establish a C57BL/6 mice colon cancer model. The radioactivity distribution of labeled 68Ga-DOTA-FL across various organs of the mouse model was examined ex-vivo. In addition, 68Ga-DOTA-FL tumor-targeted imaging in vivo was performed using small-animal PET/CT. Finally, western blotting and immunofluorescence imaging of MC38 cells and xenotransplant tumor tissues were conducted.
Results
The radiolabeling rate and radiochemical purity of 68Ga-DOTA-FL were above 95%. Both western blotting and immunofluorescence imaging revealed FAP expression in the tumor tissues, but not in the MC38 cells. Small-animal PET/CT imaging indicated that the tumor imaging was clearest at 30 min after 68Ga-DOTA-FL treatment. Examination of the radioactivity distribution in vitro revealed that at 30 min after the 68Ga-DOTA-FL treatment, the target/non-target ratio for tumor and muscle tissue was 4.0 ± 0.3 (n = 3).
Conclusions
68Ga-DOTA-FL can be used for the specific tumor imaging in mouse models, which might provide a novel alternative for FAP-targeted tumor imaging.
期刊介绍：
Clinical and Translational Imaging is an international journal that publishes timely, up-to-date summaries on clinical practice and translational research and clinical applications of approved and experimental radiopharmaceuticals for diagnostic and therapeutic purposes. Coverage includes such topics as advanced preclinical evidence in the fields of physics, dosimetry, radiation biology and radiopharmacy with relevance to applications in human subjects. The journal benefits a readership of nuclear medicine practitioners and allied professionals involved in molecular imaging and therapy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
